We describe a one-step, labeled-antibody radioassay for measuring free thyroxin (Fl4) in serum or plasma, based on a novel principle. FT4 in the sample competes with a gross molar excess (over antibody) of a cross-reactant (L-triiodothyronine, T3), chemically coupled to magnetizable polymer particles, for binding to avid '251-labeled monoclonal anti-thyroxin antibodies. As in conventional immunoassays, 'l counts bound to the solid phase (T3-magnetizable particles) are inversely proportional to sample FT4 concentration. We demonstrate here the development and technical validity of this new method.
suspension used for separation in the Amerlex-MAB4 Fr4 assay is a chemical complex of triiodothyrornne (T3) and magnetizable cellulose particles prepared as described elsewhere (23) . In brief, T3 was allowed to react with magnetizable cellulose particles (Scipac Ltd., Sittingbourne, U.K.) that had been activated with butane-1,4-diol diglycidyl ether. After washing, the unreacted groupswere blocked with ethanolamine. The T3-coupled particles were suspended in 67 mmol/L phosphate buffer, pH 6.7, prepared by dissolving potassium dihydrogen orthophosphate (40 mmolJL), disodium hydrogen orthophosphate (anhydrous; 33 mmoIIL), and sodium chloride (154 mmol/L) in de-ionized water. When this suspension was used at working strength, each assay tube contained -0.25 nmol of complexed T3.
'251..labeled monoclonal anti-T4 antibody. Monoclonal anti-T4 antibodies (IgG2B) from a mouse hybridoma, produced by using T4-bovine serum albumin (BSA) conjugate as an immunogen, were purified by diethylaminoethylcellulo8e column chromatography. The monoclonal antibody was iodinated by standard procedures with Chloramine-T (24) , to give a specific activity of -4 Ci/g of protein (148 MBq/g). The iodinated monoclonal anti-T4 antibody was purified on a TSK3000 column (Anachem Ltd., Luton, U.K.) and diluted to working strength (0.15 mCiJL, 5.6 MBqIL) in pH 7.4 phosphate buffer [dipotassium hydrogen orthophosphate (120 mmol/L) and potassium dihydrogen orthophosphate (anhydrous; 8.5 mmol/L) in water]. The buffer also contained sodium chloride (154 mmol/L), BSA (20 g/L; Biofac AJS, Copenhagen, Denmark), and sodium azide (15 mmolIL).
Antibody association constants for T4, T3, and the T3-coupled magnetizable polymer particles were determined at 37#{176}C by Scatchard analysis. The antibody was also iodinated with nonradioactive sodium iodide and the association constants of the three components were remeasured. Each assay tube contained 165 fmol of 'I-labeled antibody, the ratio of coupled T3 over antibody binding sites (assuming antibody monovalency) being 1.52 x iO/i.
Human serum standards. T4 was dissolved in resinstripped human serum to give Fr4 concentrations as measured in the assay covering the range 0 to 130 pmo]JL. These liquid standards contained sodium azide, 1 g/L, as preservative. Standards were calibrated from reference sera, prepared in a similar way, for which FF4 values had been previously assigned by an equilibrium dialysis method (25).
Labeled-AntibodyAssay of FT4
The assay was developed as a rapid, one-step method. Pipet 0.05 mL of serum standard, control, or patient's specimen in duplicate into polystyrene assay tubes. Add 0.5 mL of T3-coupled polymer particles (the separation suspension), followed by 0.5 mL of '251-labeled monoclonal anti-T4 antibody solution (tracer). Vortex-mix and incubate at 37 #{176}C for 30 mm, then place the tubes and samples on a magnetic base. After 15 mm, invert the tubes, let them drain for 5 mm, and count the remaining radioactivity for 1 mm in an NE 1600 gamma counter. The 125! counts bound are inversely proportional to Fr4 concentrations in standards (with known Fr4) and unknown samples.
Assay Validation I: Technical Validity
Equilibrium status of the assay. The equilibrium status of the assay was determined by assaying the assay standards, comparing the percentage of tracer bound to the solid phase after various incubation periods. To investigate the nature of the equilibrium, we first magnetically separated from the liquid supernate the labeled-antibody-T3-particle complex produced in an initial standard incubation. We then added to the complex another 0.05-mL aliquot of the same patient's sample as was used in the initial incubation, re-incubated the mixture, and sampled it periodically (in separate incubations) by magnetic separation.
Assay precision. Precision was determined as part of a multicenter evaluation, reported in more detail in the accompanying paper (22) . A precision-dose profile (between assays) was constructed by using sera with Fr4 concentrations spaced across the measurement range of the assay. (27) , with use of concentrations ranging from physiological or therapeutic values to a two-to 10-fold excessover those values. The same putative cross-reactants dissolved in serum were measured in a conventional F!'4 assay, and their effective contribution (as measured apparent Fr4) was determined by reference to their usual serum or therapeutic concentrations (28).
In addition, other potentially interfering substances (triolein, hemoglobin, and bilirubin) at various concentrations were added to human serum control sera containing known amounts of Fr4. #{149} NEFA addition. Various concentrations of aqueous oleic acid were used to reconstitute lyophilized delipidized euthyroid control sera containing normal concentrations of binding proteins to give a range of added NEFA (oleic acid) concentrations up to 10 mmoIJL. These samples were measured in assays with use of the tracer antibody diluted in buffer containing either BSA or casein.
Assay ValidationII: Validityof Free Hormone Results

Other Assays
Serum TBG was measured in duplicate by the Amerlite' enhanced luminescence TBG assay (Amersham International plc). HSA was measured by the bromcresol green method.
StatisticalMethods
The curve-fit method was a four-parameter logistic fit. Analysis was carried out by standard methods with LOtUS' spreadsheet and SAS' statistics package running on a Microvax computer. Linear regression was performed by the method of least squares and the correlation coefficient was determined by the method of Pearson.
Results
Assay DevelopmentCharacteristics
Antibody affinity. The affinity of the antibody for T3 was 1% of that for T4; the affinity of the antibody for (Figure 1) . At 30 mm (the assay incubation time adopted in subsequent studies), the assay was sufficiently near equilibrium for a working assay.
If both forward and back reactions were fast and contributed significantly to the equilibrium, then, in the assessment of a back reaction, a considerable fraction of the bound counts should have been moved into the solvent in a secondincubation (see Materials and Methods). However, this was not the case (Figure 2) , the back reaction being slow compared with the forward rate. After a 4-h incubation at 37#{176}C, 30% to 40% of the bound counts was lost from the solid phase.
Dose-response study.
The dose-response curve is shown in Figure 3 T3 was 1.2%; with "reverse T3" (L-3,3',5'-triiodothyronine) it was 15.6% (see Table 2 for these and other cross-reacting substances). The effective contribution of these cross-reactivities to measured Fr4 concentrations for these substances was in all cases <0.3 pmol/L ( Table   2 ).
The effect of potentially interfering substances-triolein (representing triglycerides), hemoglobin, and bilirubin-was small at the concentrations used. The change in values for three control sera (nominally 5.5, 17.3, and 48 pmol/L for controls A, B, and C, respectively) with increasing amounts of the substances is shown in Figure 4 .
Validity of Measurements of Free Hormones
Sampling of T4 by tracer antibody. The extent to which T4 was bound to the antibody in the various sera in standard assay conditions was determined as 1.0%
(hyperthyroid patient's sample), 0.6% (euthyroid, normal TBG), 1.6% (hypothyroid), 0.4% (late pregnancy), and 3.0% (euthyroid, TBG-deficient).
Influence of serum T4-binding proteins.
Addition of
increasing amounts of T4-stripped binding proteins to the assay's zero standard had a slight effect on the B0 of the assay. The presence of TBG concentrations up 150 mgfL (in addition to the 20 mgfL present in this standard) and transthyretin up to 600 mg/L (in addition to the 400 mg/L present in the standard) decreased the B0 by 3%. HSA up to 100 g/L had no apparent effect on assay B0 (Figure 5) . We have demonstrated the characteristics and validity of the AmerlexMAB* Fr4 assay. This one-step assay apparently proceeds to equilibrium after 30 mm at 37#{176}C. This rapid progression to equilibrium is due to the novel design, wherein essentially unchanging (gross molar excess) concentrations of antibody "cross-reactant" coupled chemically to solid-phase polymer particles compete with Fr4 for binding sites on a limited quantity of radiolabeled antibody. In contrast to the rapid forward reaction, the back reaction of dissociation of antibody bound to the solid phase in the presence of further Fr4 is slow.
This result may in part be due to the high local surface concentration of T3, which would favor re-association of the antibody to the solid phase rather than its displacement by lower local concentrations of Fr4. The sample Fr4 concentration remains constant, because the T4-binding proteins release T4 in response to antibody uptake (30), as does the concentration of unbound T3 on the solid phase, owing to its gross excess over available binding antibody. These two competing forms thus effectively saturate the antibody by essentially unidirectional kinetics, so that significant back-reactions are not favored.
The agreement with a dialysis Fr4 and a two-step Fr4 method was good, with correlation coefficients 0.90 for results for sara containing various TBG concentrations. That an exact numerical agreement with these two "reference" methods was not observed reflects the continuing difficulty of assessing accuracy in methods for free thyroid hormones, even when comparing two "goldstandard" tests (31).
The cross-reactivity of the antibody for the major serum cross-reactant T3 is low (-1%) and, although the cross-reactivity of "reverse T3" is 15%, its presence in much lower physiological concentrations than T3 ensures that the effective contribution of reverse T3 to measured Fr4 estimates is <0.05 pmol/L. In addition there was a The small amount of tracer antibody used in the assay ensures that the disturbance of the bound-free equilibrium for T4 in the serum sample is within accepted limits (32). Even for a sample from a subject with a congenital TBG-deflciency, the tracer antibody sequesters only 3% of the total T4. In these sera, the percentage of total T4 in the unbound state has been calculated to be about threefold greater than in normal-TBG sera (33). One can be confident from this extreme example that all sera will obey the essential criterion of minimal disturbance of Fr4 by antibody sampling.
The dilution of serum samples (in addition to the dilution factor of 21 intrinsic in the assay conditions) causes a decrease in Fr4 estimates. This decrease upon dilution is probably caused largely by the dissimilarity between the assay diluents (containing BSA to buffer the effects of the NEFA that developed upon storage of serum in vitro) and the diluted sample. However, this change in measured FT4 after sample dilution is of no consequence when the assay is used in the standard protocol, when both the assay standards and the unknown samples are treated identically.
When oleic acid (NEFA) is added to serum at a concentration of 5 mniol/L, the Fr4 estimate increases by 12% as T4 is displaced from the binding proteins. A recent evaluation of the AmerlexMAB* Fr4 method confirmed this observation (34) and showed that, at the same NEFA concentration, Fr4 measured by a two-step method increased by 70%. The experimental addition of NEFA is of significance when supraphysiological concentrations of NEFA are produced in vitro (35,36) after heparin administration. These high NEFA concentrations may cause an increase in Fr4 that is inconsistent with the thyroid status of the patient when Fr4 assays that are not robust to changes in NEFA concentrations are used.
Aside from patients infused with heparin, physiological concentrations of NEFA are unlikely to be high enough to displace T4 and thus cause an increase in Fr4 (37) . However, as Nicholson et al. found (37) NEFA causes an initial decrease of measured Fr4, before T4 displacement from albumin at higher NEFA concentrations increases the measurements (7) . The effect of including BSA in the assay diluent buffers on serum Fr4 measurements was as expected. As predicted by the Law of Mass Action (29), the expected decrease in Fr4 estimates was noted for both a normal-TBG and a TBG-deficient serum when increasing amounts of albumin were added to the sera. When a protein lacking thyroid hormone-binding capability (casein) was substituted for BSA, the robustness of serum samples to dilution increased markedly, concomitant with an increased sensitivity to increases in NEFA concentrations. Thus, the presence of BSA in the assay buffers represents a trade-off between increased robustness of the assay towards adventitious increases in NEFA or other interferents in serum in vitro and decreased robustness of Fr4 measurements to serum dilution.
It has also been demonstrated that none of the common T4-binding proteins in serum interfere in the assay. This was researched especially carefully for HSA, is supported technically by clinical data (4,22,40) , and is thus in marked contrast to the difficulties encountered in first-generation analog VP4 assays (2, 10, 41-43 ).
Subsequently, analog-type Fr4 assays have been developed with protein-T4 analogs (e.g., the Amerlite Fr4 assay, [44] [45] [46] . Like the assay described here, these do not show tracer binding by the normal serum proteins, though interference from rarely encountered thyroid hormone autoantibodies (47, 48) may occur.
In conclusion, we have shown the validity of the 
